Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00621751 · ClinicalTrials.gov registry record · NA

Carbamazepine for the Treatment of Chronic Post-Traumatic Brain Injury Irritability and Aggression

A NA study of Traumatic Brain Injury, sponsored by Wake Forest University Health Sciences.

Completed
Registry status
NA
Development phase
70
Enrollment target
1
Study location

NCT00621751 is a NA study of Traumatic Brain Injury that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 70 participants, below the 277-participant average among 171 other Traumatic Brain Injury trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00621751, a NA study of Traumatic Brain Injury, has completed, sponsored by Wake Forest University Health Sciences.

COMPLETED
Registry status
NA
Development phase
70 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine if carbamazepine reduces irritability and aggression among individuals with traumatic brain injury

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Carbamazepine

Study Locations (1)

North Carolina

  • Carolinas Rehabilitation - Charlotte

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2008-02
Est. Completion 2013-10
Phase NA

Sponsor

Wake Forest University Health Sciences

1,140 total trials

What the Registry Record Tells You About NCT00621751

The ClinicalTrials.gov registry entry for NCT00621751 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 277-participant average among 171 other Traumatic Brain Injury trials with a reported enrollment target (75% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Traumatic Brain Injury appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00621751 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT00621751 about?

NCT00621751 is a clinical study titled "Carbamazepine for the Treatment of Chronic Post-Traumatic Brain Injury Irritability and Aggression". The purpose of this study is to determine if carbamazepine reduces irritability and aggression among individuals with traumatic brain injury

What is the current status of trial NCT00621751?

This trial is currently completed. It is a NA study. The enrollment target is 70 participants. The study started on 2008-02. Estimated completion is 2013-10.

What conditions does trial NCT00621751 study?

This clinical trial studies the following conditions: Traumatic Brain Injury.

What interventions are being tested in trial NCT00621751?

The interventions under investigation include: Placebo (DRUG), Carbamazepine (DRUG).

Who is sponsoring clinical trial NCT00621751?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00621751 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Traumatic Brain Injury

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.